EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations

Maudy T M Theunissen iD, Zohra Hayat iD, Françoise Bouhour iD, Johanna M P van den Hout iD, Jean-Baptiste Noury, Emmeline Lagrange, Aurélie Jouy, Nadjib Taouagh, Pieter A van Doorn iD, Ans T van der Ploeg iD, Pascal Laforêt iD, Nadine A M E van der Beek iD

European Journal of Neurology · 2026-06 · 33 (6)

DOI: 10.1111/ene.70648 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2026-06-25. Written by Maudy T M Theunissen and 11 co-authors. Institution: Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Major MEDLINE topics: Glycogen Storage Disease Type II, Enzyme Replacement Therapy, Pregnancy Complications. 51 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Helen Walker Research Grant.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

There are no clear guidelines for enzyme replacement therapy (ERT) use and obstetric management in pregnant patients with Pompe disease receiving ERT. This study aims to explore outcomes and challenges for these patients.

Methods

We included French and Dutch patients who became pregnant during ERT. Main outcomes were pregnancy (ERT management, obstetric delivery, neonatal outcomes) and clinical results (6‐min walk test [6MWT], forced vital capacity [FVC] in supine and upright positions, infusion associated reactions [IARs]).

Results

Data from 11 patients (median age at pregnancy onset 33 years) with 14 pregnancies were studied. One pregnancy ended in early miscarriage, and 12/13 live births reached term. Eight pregnancies had an induced birth or planned C‐section, 6/8 due to maternal condition (e.g., increased dyspnea or preference medical team to ensure patient's safety). ERT was continued in eight pregnancies, with three patients receiving an adjusted dose based on their increased weight. ERT was interrupted early in five pregnancies because of trial participation or safety concerns. No IARs were reported during pregnancy or after restart of ERT. Of the patients with clinical data during pregnancy, a (mild) decline was observed in 6/7 pregnancies for 6MWT, 3/10 for upright FVC, and 6/9 for supine FVC. Most patients recovered from their decline during pregnancy within 2 years.

Conclusion

In patients who continued ERT during pregnancy, it appeared to be safe, with no documented adverse effects for mother or child. While most patients experienced a mild worsening of clinical condition during pregnancy, the majority recovered well postpartum.

Subjects

MeSH terms (MEDLINE)

Glycogen Storage Disease Type IIEnzyme Replacement TherapyPregnancy ComplicationsHumansFemalePregnancyAdultPregnancy Outcome

Author keywords

Pompe diseaseenzyme replacement therapyglycogen storage disease type IIobstetric managementpregnancy

Authors and institutions

  • Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC-Sophia Children's Hospital, University Medical Center, Rotterdam, the Netherlands.
  • Service d'Electroneuromyographie et Pathologies Neuromusculaires, Reference Center for Neuromuscular Diseases PACARARe, Hospices Civils de Lyon, Lyon, France.
  • Neurophysiology Department, Centre Hospitalier Universitaire de Brest, Reference Centre for Neuromuscular Diseases AOC, LBAI INSERM UMR 1227, Brest, France.
  • Department of Neurology, Grenoble University Hospital, Grenoble, France.
  • Department of Neurology, Nord/Est/Île-de-France Neuromuscular Reference Center, FHU PHENIX, AP-HP, Raymond-Poincaré Hospital, Garches, France.

ORCID profiles: Maudy T M Theunissen, Zohra Hayat, Françoise Bouhour, Johanna M P van den Hout, Pieter A van Doorn, Ans T van der Ploeg, Pascal Laforêt, Nadine A M E van der Beek

Funding

  • Helen Walker Research Grant

Cite

APA

Theunissen, M. T. M., Hayat, Z., Bouhour, F., van den Hout, J. M. P., Noury, J. B., Lagrange, E., Jouy, A., Taouagh, N., van Doorn, P. A., van der Ploeg, A. T., Laforêt, P., & van der Beek, N. A. M. E. (2026). Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70648

Vancouver

Theunissen MTM, Hayat Z, Bouhour F, van den Hout JMP, Noury JB, Lagrange E, et al. Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70648

BibTeX
@article{Theunissen2026,
  author = {Theunissen, Maudy T M and Hayat, Zohra and Bouhour, Françoise and van den Hout, Johanna M P and Noury, Jean-Baptiste and Lagrange, Emmeline and Jouy, Aurélie and Taouagh, Nadjib and van Doorn, Pieter A and van der Ploeg, Ans T and Laforêt, Pascal and van der Beek, Nadine A M E},
  title = {Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {6},
  doi = {10.1111/ene.70648}
}
Start for free →